Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
181 hedge funds and large institutions have $1.45B invested in Impax Laboratories, Inc. in 2014 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 71 increasing their positions, 61 reducing their positions, and 18 closing their positions.
89% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 18
66% more call options, than puts
Call options by funds: $8.63M | Put options by funds: $5.18M
16% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 61
9% more funds holding
Funds holding: 166 → 181 (+15)
8% more capital invested
Capital invested by funds: $1.34B → $1.45B (+$108M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$27.7M |
| 2 |
Millennium Management
New York
|
+$11.8M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$10.2M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$9.82M |
| 5 |
PC
PointState Capital
New York
|
+$8.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
-$25.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.9M |
| 3 |
Neuberger Berman Group
New York
|
-$10.5M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$9.51M |
| 5 |
Renaissance Technologies
New York
|
-$9.05M |
IPXL Hedge Fund Activity: Q1 2014 in Review
181 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q1 2014, worth a combined $1.45B — up 8.1% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IPXL positions and 18 closed out — a net gain of 16 holders — while 71 added to existing stakes and 61 trimmed.
The largest buyer was OrbiMed, adding an estimated $27.7M. The largest seller was RS Investment Management, cutting an estimated $25.5M.
- 181 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q1 2014, up from 166 in Q4 2013.
- Funds reported $1.45B of Impax Laboratories, Inc. stock for Q1 2014, up 8.1% quarter-over-quarter.
- 34 funds opened new Impax Laboratories, Inc. positions in Q1 2014 and 18 closed out, a net change of +16 holders.
- The largest Impax Laboratories, Inc. buyer in Q1 2014 was OrbiMed, an estimated $27.7M added.
- The largest Impax Laboratories, Inc. seller in Q1 2014 was RS Investment Management, an estimated $25.5M sold.
Based on aggregated 13F filings for Q1 2014.